<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01592799</url>
  </required_header>
  <id_info>
    <org_study_id>114004</org_study_id>
    <nct_id>NCT01592799</nct_id>
  </id_info>
  <brief_title>Study on the Burden of Influenza-related Hospitalizations and Emergency Room (ER) Visits in Children in Spain</brief_title>
  <official_title>Burden of Influenza-related Hospitalizations and Emergency Room Visits in Children in Spain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study aims to quantify the inpatient and ER visits burden of laboratory-confirmed
      influenza, and compare the clinical features, severity, complications, risk factors and
      socioeconomic impact of influenza in children presenting with acute respiratory illness (ARI)
      and/or isolated fever, with or without laboratory-confirmed influenza.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total medical cost associated with each hospitalization or ER visit will also be
      calculated at the end of this study.

      The study will be conducted from October, 2010, until May, 2011. Each subject will be
      followed-up for 21-30 days via telephone. The follow-up medical chart review will preferably
      be performed within 7 days after the telephone contact.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 23, 2010</start_date>
  <completion_date type="Actual">May 23, 2011</completion_date>
  <primary_completion_date type="Actual">May 23, 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Laboratory-confirmed Influenza Presenting With an Acute Respiratory Illness (ARI) and/or Isolated Fever</measure>
    <time_frame>Day 0 till Day 28-37</time_frame>
    <description>ARI was defined as one or more of the following symptoms: sore throat (in children greater than or equal to (≥) 3 years old), coryza (runny nose), cough, breathing difficulties. Isolated fever was defined as: oral temperature ≥37.5°C / axillary temperature ≥37.5°C / Rectal temperature ≥38°C / tympanic temperature on oral setting ≥37.5°C / tympanic temperature on rectal setting ≥38°C without an obvious cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Direct Medical Cost Per Hospitalization or ER Visit With Laboratory-confirmed Influenza</measure>
    <time_frame>Day 0 till Day 28-37</time_frame>
    <description>Ward specific room charge and Intensive Care Unit (ICU) were computed as daily charge multiplied by the number of days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Other Laboratory-confirmed Respiratory Viruses</measure>
    <time_frame>Day 0 till Day 28-37</time_frame>
    <description>Among the other laboratory-confirmed respiratory viruses there were:adenovirus, respiratory syncytial virus, parainfluenza virus 1, 2 and 3, metapneumovirus, bocavirus, rhinovirus or coronavirus. The outcome was assessed in subjects with an acute respiratory illness (ARI) and/or isolated fever episode.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Fatal Outcomes</measure>
    <time_frame>Day 0 till Day 28-37</time_frame>
    <description>Deaths from ARI and/or fever episodes by laboratory-confirmed influenza status were assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Secondary Bacterial Infections</measure>
    <time_frame>Day 0 till Day 28-37</time_frame>
    <description>The outcome assessed the various complications by laboratory-confirmed influenza status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Potential Risk Factors at Study Start by Laboratory-confirmed Influenza Status</measure>
    <time_frame>Day 0 till Day 28-37</time_frame>
    <description>Risk factors were classified as pre-existing conditions, breast-feeding status and day-care status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Hospitalization</measure>
    <time_frame>Day 0 till Day 28-37 (between October 2010 until May 2011)</time_frame>
    <description>The outcomes was assessed in subjects with laboratory-confirmed influenza status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Using Any ARI and/or Fever Related Medication Taken Prior to Hospitalization or ER Visit by Laboratory-confirmed Influenza Status</measure>
    <time_frame>Day 0 till Day 28-37</time_frame>
    <description>ARI and/or fever related medication included: antivirals, antibiotics, cough suppressants, pain medication, antipyretics and mucolytics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Using Any ARI and/or Fever Related Medication Prescribed During Hospitalization or ER Visit by Laboratory-confirmed Influenza Status</measure>
    <time_frame>Day 0 till Day 28-37</time_frame>
    <description>ARI and/or fever related medication included: antivirals, antibiotics, cough suppressants, pain medication, antipyretics and mucolytics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Using Any ARI and/or Fever Related Medication Prescribed Since Hospitalization or ER Visit by Laboratory-confirmed Influenza Status</measure>
    <time_frame>Day 0 till Day 28-37</time_frame>
    <description>ARI and/or fever related medication included: antivirals, antibiotics, cough suppressants, pain medication, antipyretics and mucolytics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Using Any Non-prescribed ARI and/or Fever Related Medication Taken Since Hospitalization or ER Visit</measure>
    <time_frame>Day 0 till Day 28-37</time_frame>
    <description>ARI and/or fever related medication included: antivirals, antibiotics, cough suppressants, pain medication, antipyretics and mucolytics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of School Absenteeism</measure>
    <time_frame>Day 0 till Day 28-37</time_frame>
    <description>School absenteeism was assessed among patients during the follow-up period by laboratory-confirmed influenza status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Parent or Caregiver Time Off Work</measure>
    <time_frame>Day 0 till Day 28-37</time_frame>
    <description>This outcome assessed absenteeism among caregivers to provide patient care during the follow-up period by laboratory-confirmed influenza status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Household Members With Influenza-like Illness</measure>
    <time_frame>Day 0 till Day 28-37</time_frame>
    <description>This outcome assessed the number of cases with household contacts presenting influenza like illness symptoms during the follow-up period by laboratory-confirmed influenza status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Household Members Presenting Influenza Like Illness Symptoms (ARI and/or Isolated Fever)</measure>
    <time_frame>Day 0 till Day 28-37</time_frame>
    <description>This outcome assessed the proportion of influenza like illness (ILI) among household members of children &lt; 15 years with and without laboratory-confirmed influenza.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">501</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Influenza Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Children &lt;15 years of age hospitalized for or presenting to an ER for acute ARI and/or isolated fever during the influenza season.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Throat swab and/or nasopharyngeal swab</intervention_name>
    <description>Samples will be tested to quantify the inpatient and ER visits burden of laboratory-confirmed influenza.</description>
    <arm_group_label>Influenza Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>Log Sheet will be used to collected data on a monthly basis for the following age groups: &lt; 6 months; 6-23 months; 24-59 months; &gt; 5 years.</description>
    <arm_group_label>Influenza Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects for whom the investigator believes that they and/or their parents/guardians
             can and will comply with the requirements of the protocol.

          -  A male or female &lt;15 years of age at the time of study entry. A subject will become
             ineligible on his/her 15th birthday.

          -  Signed informed consent from the parents or guardians of the subject and signed assent
             from children ≥ 12 years old.

          -  Presenting with a sudden onset clinical process comprising :

               -  Isolated fever defined as: oral temperature ≥ 37.5°C / axillary temperature ≥
                  37.5°C / Rectal temperature ≥ 38°C / tympanic temperature on oral setting ≥
                  37.5°C / tympanic temperature on rectal setting ≥ 38°C without an obvious cause.

        And/or

          -  ARI defined as one or more of the following symptoms: sore throat, coryza, cough,
             breathing difficulties.

        Exclusion Criteria:

        • Children in foster care.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 3, 2012</study_first_submitted>
  <study_first_submitted_qc>May 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2012</study_first_posted>
  <results_first_submitted>September 20, 2017</results_first_submitted>
  <results_first_submitted_qc>June 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 27, 2018</results_first_posted>
  <last_update_submitted>June 12, 2018</last_update_submitted>
  <last_update_submitted_qc>June 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Children</keyword>
  <keyword>Hospitalizations</keyword>
  <keyword>Spain</keyword>
  <keyword>Burden</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment started in October, 2010, and last until May, 2011, or until the target sample size was enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Influenza Group</title>
          <description>Children &lt;15 years of age hospitalized for or presenting to an Emergency Room (ER) for Acute Respiratory Illness (ARI) and/or isolated fever during the influenza season.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="501"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="501"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Influenza Group</title>
          <description>Children less than (&lt;) 15 years of age hospitalized for or presenting to an ER for acute ARI and/or isolated fever during the influenza season.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="501"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.0" spread="37.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Laboratory-confirmed Influenza Presenting With an Acute Respiratory Illness (ARI) and/or Isolated Fever</title>
        <description>ARI was defined as one or more of the following symptoms: sore throat (in children greater than or equal to (≥) 3 years old), coryza (runny nose), cough, breathing difficulties. Isolated fever was defined as: oral temperature ≥37.5°C / axillary temperature ≥37.5°C / Rectal temperature ≥38°C / tympanic temperature on oral setting ≥37.5°C / tympanic temperature on rectal setting ≥38°C without an obvious cause.</description>
        <time_frame>Day 0 till Day 28-37</time_frame>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Group</title>
            <description>Children &lt;15 years of age hospitalized for or presenting to an ER for ARI and/or isolated fever during the influenza season.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Laboratory-confirmed Influenza Presenting With an Acute Respiratory Illness (ARI) and/or Isolated Fever</title>
          <description>ARI was defined as one or more of the following symptoms: sore throat (in children greater than or equal to (≥) 3 years old), coryza (runny nose), cough, breathing difficulties. Isolated fever was defined as: oral temperature ≥37.5°C / axillary temperature ≥37.5°C / Rectal temperature ≥38°C / tympanic temperature on oral setting ≥37.5°C / tympanic temperature on rectal setting ≥38°C without an obvious cause.</description>
          <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Emergency Room</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Direct Medical Cost Per Hospitalization or ER Visit With Laboratory-confirmed Influenza</title>
        <description>Ward specific room charge and Intensive Care Unit (ICU) were computed as daily charge multiplied by the number of days.</description>
        <time_frame>Day 0 till Day 28-37</time_frame>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available and who were hospitalized or visited an emergency room.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Group</title>
            <description>Children &lt;15 years of age hospitalized for or presenting to an ER for ARI and/or isolated fever during the influenza season.</description>
          </group>
        </group_list>
        <measure>
          <title>Direct Medical Cost Per Hospitalization or ER Visit With Laboratory-confirmed Influenza</title>
          <description>Ward specific room charge and Intensive Care Unit (ICU) were computed as daily charge multiplied by the number of days.</description>
          <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available and who were hospitalized or visited an emergency room.</population>
          <units>Euros</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Laboratory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.27" spread="48.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.94" spread="9.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other diagnostics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.94" spread="80.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total for diagnostics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.97" spread="63.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prescribed medication [given in the hospital]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.52" spread="10.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prescribed medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.28" spread="18.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-prescribed medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.86" spread="12.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total for treatments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.44" spread="21.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ward specific room charge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1774.55" spread="1062.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1535.19" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total for inpatient charge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1884.21" spread="1182.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ER visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170.16" spread="64.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.77" spread="49.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Other Laboratory-confirmed Respiratory Viruses</title>
        <description>Among the other laboratory-confirmed respiratory viruses there were:adenovirus, respiratory syncytial virus, parainfluenza virus 1, 2 and 3, metapneumovirus, bocavirus, rhinovirus or coronavirus. The outcome was assessed in subjects with an acute respiratory illness (ARI) and/or isolated fever episode.</description>
        <time_frame>Day 0 till Day 28-37</time_frame>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Group</title>
            <description>Children &lt;15 years of age hospitalized for or presenting to an ER for ARI and/or isolated fever during the influenza season.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Other Laboratory-confirmed Respiratory Viruses</title>
          <description>Among the other laboratory-confirmed respiratory viruses there were:adenovirus, respiratory syncytial virus, parainfluenza virus 1, 2 and 3, metapneumovirus, bocavirus, rhinovirus or coronavirus. The outcome was assessed in subjects with an acute respiratory illness (ARI) and/or isolated fever episode.</description>
          <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Emergency Room</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Fatal Outcomes</title>
        <description>Deaths from ARI and/or fever episodes by laboratory-confirmed influenza status were assessed.</description>
        <time_frame>Day 0 till Day 28-37</time_frame>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Positive Group</title>
            <description>Children &lt;15 years of age with at least one laboratory test positive for influenza.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Negative Group</title>
            <description>Children &lt;15 years of age with no laboratory test positive for influenza.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Fatal Outcomes</title>
          <description>Deaths from ARI and/or fever episodes by laboratory-confirmed influenza status were assessed.</description>
          <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Secondary Bacterial Infections</title>
        <description>The outcome assessed the various complications by laboratory-confirmed influenza status.</description>
        <time_frame>Day 0 till Day 28-37</time_frame>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Positive Group</title>
            <description>Children &lt;15 years of age with at least one laboratory test positive for influenza.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Negative Group</title>
            <description>Children &lt;15 years of age with no laboratory test positive for influenza.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Secondary Bacterial Infections</title>
          <description>The outcome assessed the various complications by laboratory-confirmed influenza status.</description>
          <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any complication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary bacterial pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primary influenza viral pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronchiolitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Otitis Media</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myositis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pericarditis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctivitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Potential Risk Factors at Study Start by Laboratory-confirmed Influenza Status</title>
        <description>Risk factors were classified as pre-existing conditions, breast-feeding status and day-care status.</description>
        <time_frame>Day 0 till Day 28-37</time_frame>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Positive Group</title>
            <description>Children &lt;15 years of age with at least one laboratory test positive for influenza.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Negative Group</title>
            <description>Children &lt;15 years of age with no laboratory test positive for influenza.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Potential Risk Factors at Study Start by Laboratory-confirmed Influenza Status</title>
          <description>Risk factors were classified as pre-existing conditions, breast-feeding status and day-care status.</description>
          <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pre-existing conditions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No pre-existing conditions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prematurity (&lt;36 weeks gestation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic pneumopathy (including asthma)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neuromuscular diseases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast fed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not breast fed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast feeding status not known (&gt;2 years old)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In day-care attendance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not in day-care attendance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not known if in day-care attendance (&gt;5 years old)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Hospitalization</title>
        <description>The outcomes was assessed in subjects with laboratory-confirmed influenza status</description>
        <time_frame>Day 0 till Day 28-37 (between October 2010 until May 2011)</time_frame>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Positive Group</title>
            <description>Children &lt;15 years of age with at least one laboratory test positive for influenza.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Negative Group</title>
            <description>Children &lt;15 years of age with no laboratory test positive for influenza.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Hospitalization</title>
          <description>The outcomes was assessed in subjects with laboratory-confirmed influenza status</description>
          <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.00"/>
                    <measurement group_id="O2" value="4.4" spread="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Using Any ARI and/or Fever Related Medication Taken Prior to Hospitalization or ER Visit by Laboratory-confirmed Influenza Status</title>
        <description>ARI and/or fever related medication included: antivirals, antibiotics, cough suppressants, pain medication, antipyretics and mucolytics.</description>
        <time_frame>Day 0 till Day 28-37</time_frame>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Positive Group</title>
            <description>Children &lt;15 years of age with at least one laboratory test positive for influenza.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Negative Group</title>
            <description>Children &lt;15 years of age with no laboratory test positive for influenza.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Using Any ARI and/or Fever Related Medication Taken Prior to Hospitalization or ER Visit by Laboratory-confirmed Influenza Status</title>
          <description>ARI and/or fever related medication included: antivirals, antibiotics, cough suppressants, pain medication, antipyretics and mucolytics.</description>
          <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antibiotics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough suppressants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antihistamines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucolytics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Using Any ARI and/or Fever Related Medication Prescribed During Hospitalization or ER Visit by Laboratory-confirmed Influenza Status</title>
        <description>ARI and/or fever related medication included: antivirals, antibiotics, cough suppressants, pain medication, antipyretics and mucolytics.</description>
        <time_frame>Day 0 till Day 28-37</time_frame>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Positive Group</title>
            <description>Children &lt;15 years of age with at least one laboratory test positive for influenza.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Negative Group</title>
            <description>Children &lt;15 years of age with no laboratory test positive for influenza.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Using Any ARI and/or Fever Related Medication Prescribed During Hospitalization or ER Visit by Laboratory-confirmed Influenza Status</title>
          <description>ARI and/or fever related medication included: antivirals, antibiotics, cough suppressants, pain medication, antipyretics and mucolytics.</description>
          <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any medication prescribed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antivirals</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antibiotics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough suppressants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucolytics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Using Any ARI and/or Fever Related Medication Prescribed Since Hospitalization or ER Visit by Laboratory-confirmed Influenza Status</title>
        <description>ARI and/or fever related medication included: antivirals, antibiotics, cough suppressants, pain medication, antipyretics and mucolytics.</description>
        <time_frame>Day 0 till Day 28-37</time_frame>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Positive Group</title>
            <description>Children &lt;15 years of age with at least one laboratory test positive for influenza.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Negative Group</title>
            <description>Children &lt;15 years of age with no laboratory test positive for influenza.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Using Any ARI and/or Fever Related Medication Prescribed Since Hospitalization or ER Visit by Laboratory-confirmed Influenza Status</title>
          <description>ARI and/or fever related medication included: antivirals, antibiotics, cough suppressants, pain medication, antipyretics and mucolytics.</description>
          <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any medication prescribed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antivirals</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antibiotics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough suppressants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antihistamines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucolytics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Using Any Non-prescribed ARI and/or Fever Related Medication Taken Since Hospitalization or ER Visit</title>
        <description>ARI and/or fever related medication included: antivirals, antibiotics, cough suppressants, pain medication, antipyretics and mucolytics.</description>
        <time_frame>Day 0 till Day 28-37</time_frame>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Positive Group</title>
            <description>Children &lt;15 years of age with at least one laboratory test positive for influenza.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Negative Group</title>
            <description>Children &lt;15 years of age with no laboratory test positive for influenza.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Using Any Non-prescribed ARI and/or Fever Related Medication Taken Since Hospitalization or ER Visit</title>
          <description>ARI and/or fever related medication included: antivirals, antibiotics, cough suppressants, pain medication, antipyretics and mucolytics.</description>
          <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any non-prescribed medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antibiotics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antihistamines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucolytics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of School Absenteeism</title>
        <description>School absenteeism was assessed among patients during the follow-up period by laboratory-confirmed influenza status.</description>
        <time_frame>Day 0 till Day 28-37</time_frame>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Positive Group</title>
            <description>Children &lt;15 years of age with at least one laboratory test positive for influenza.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Negative Group</title>
            <description>Children &lt;15 years of age with no laboratory test positive for influenza.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of School Absenteeism</title>
          <description>School absenteeism was assessed among patients during the follow-up period by laboratory-confirmed influenza status.</description>
          <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="3.46"/>
                    <measurement group_id="O2" value="6.4" spread="3.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Parent or Caregiver Time Off Work</title>
        <description>This outcome assessed absenteeism among caregivers to provide patient care during the follow-up period by laboratory-confirmed influenza status.</description>
        <time_frame>Day 0 till Day 28-37</time_frame>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Positive Group</title>
            <description>Children &lt;15 years of age with at least one laboratory test positive for influenza.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Negative Group</title>
            <description>Children &lt;15 years of age with no laboratory test positive for influenza.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Parent or Caregiver Time Off Work</title>
          <description>This outcome assessed absenteeism among caregivers to provide patient care during the follow-up period by laboratory-confirmed influenza status.</description>
          <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="2.76"/>
                    <measurement group_id="O2" value="4.1" spread="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Household Members With Influenza-like Illness</title>
        <description>This outcome assessed the number of cases with household contacts presenting influenza like illness symptoms during the follow-up period by laboratory-confirmed influenza status.</description>
        <time_frame>Day 0 till Day 28-37</time_frame>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Positive Group</title>
            <description>Children &lt;15 years of age with at least one laboratory test positive for influenza.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Negative Group</title>
            <description>Children &lt;15 years of age with no laboratory test positive for influenza.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Household Members With Influenza-like Illness</title>
          <description>This outcome assessed the number of cases with household contacts presenting influenza like illness symptoms during the follow-up period by laboratory-confirmed influenza status.</description>
          <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
          <units>Household members</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Household members with influenza-like illness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Household members with no influenza-like illness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-2 household members with ARI/fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-4 household members with ARI/fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;4 household members with ARI/fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing confirmed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Household Members Presenting Influenza Like Illness Symptoms (ARI and/or Isolated Fever)</title>
        <description>This outcome assessed the proportion of influenza like illness (ILI) among household members of children &lt; 15 years with and without laboratory-confirmed influenza.</description>
        <time_frame>Day 0 till Day 28-37</time_frame>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Positive Group</title>
            <description>Children &lt;15 years of age with at least one laboratory test positive for influenza.</description>
          </group>
          <group group_id="O2">
            <title>Influenza Negative Group</title>
            <description>Children &lt;15 years of age with no laboratory test positive for influenza.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Household Members Presenting Influenza Like Illness Symptoms (ARI and/or Isolated Fever)</title>
          <description>This outcome assessed the proportion of influenza like illness (ILI) among household members of children &lt; 15 years with and without laboratory-confirmed influenza.</description>
          <population>The analysis was performed on the according-to-protocol (ATP) cohort for analysis, which included all evaluable subjects (i.e. those meeting all eligibility criteria and complying with the procedures defined in the protocol) for whom data concerning endpoint measures were available.</population>
          <units>Percentage of household members</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.80" lower_limit="21.16" upper_limit="31.06"/>
                    <measurement group_id="O2" value="17.45" lower_limit="15.02" upper_limit="20.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>No solicited or unsolicited adverse events were collected during this study. No SAEs or fatal events were recorded during this study.</time_frame>
      <desc>Serious and non-serious adverse events were not planned to be assessed as part of this study protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>Influenza Group</title>
          <description>Children &lt;15 years of age hospitalized for or presenting to an ER for acute ARI and/or isolated fever during the influenza season.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

